FOUNDERS: Diane and Michael Fagen

Contact Info: dianef84@yahoo.com

Home

My Blog

Links

Introduction

Our Mission and our Goals

The Precautionary Principle

What is a Reportable Disease

List of Reportable Diseases and REGULATIONS PRESCRIBING CERTAIN DISEASES AS REPORTABLE DISEASES

Public Health Act

What is Mycobacterium avium Paratuberculosis

Research

La Presse,  April 8, 2001,  Never in My Milk? by Marie France Coutu

The Canadian Media

Canadian Medical and Government

Canadian Veterinary

CTV News Report, September  4th, 2001, Researchers Link Cow's Milk to Crohn's Disease

Let's Talk

Taking Action

The Message Board

Link To Us

Does Mycobacterium Paratuberculosis cause Crohn's disease by Alan Kennedy  

(PARA) PARATUBERCULOSIS AWARENESS & RESEARCH ASS.,INC

International Ass. for Paratuberculosis Copyright © 1999-2001

Crohn's Disease Info Center by Dr. Ira Shafran

The Johne's Information Center

History of Early Research on Crohn's disease

Regional Ileitis by Dr. B. Crohn

Got Milk? by Michael Greger, MD Updated January 2001

THE CROHN'S CONNECTION  by Lisa Chamberlain

Dire Warnings About Johne’s
Disease A wake-up call for the dairy industry? January 1998, University of Wisconsin, School of Veterinary Medicine

Dr. Chiodini's Tables

American and European Links

University of Wisconsin School of Veterinary Medicine

Crohn's Family Support Group

ACTION RESEARCH

Canadian Animal CAHNet Health Network

Canadian Bacterial Diseases Network

FOOD STANDARDS ASSOCIATION

IBD Forum

University of Guelph

NACC

Continued next page

We at MAP-Canada would like to dedicate this site to Doctor Rod Chiodini (U.S.A.) and Doctor John Hermon-Taylor of the U.K. and to my husband Michael Fagen, who lost his 27 year valiant battle against Crohn's disease on May 11th, 2003.

Dr Rod Chiodini (Rhode Island Hospital and Brown University, Providence, RI, USA) and Prof. John Hermon-Taylor (St. George's Hospital Medical School, London, UK) are two of the most prominent proponents of an association between M. paratuberculosis and Crohn's disease. Indeed it was Chiodini and his co-workers who, in 1984, successfully cultured the first two strains of M. paratuberculosis in the USA from patients with Crohn's disease. Since then this organism has been sporadically cultured from humans with Crohn's disease and a total of 10 isolates of M. paratuberculosis had been cultured from patients with Crohn's disease in the USA, Australia, the Netherlands and France (Chiodini, 1989).http://www.catcha.com.sg/cgi-bin/redirect.cgi?url=http://www.ifst.org/hottop23.htm

.Join Us In Our Fight with the Canadian Government to add Johne's disease in cattle to their of Reportable Diseases List in order to eliminate this bacterium from the Canadian Food Chain.

Researchers in many parts of the world have found a link between Crohn's disease in humans and Johne's disease in cattle. This bacterium is called MAP (Mycobacterium avium Paratuberculosis). This bacterium has been found in the breast milk of breastfeeding mothers with Crohns.  It has been found in the resected tissues of the intestinal tract of Crohn's sufferers and it has been found in milk after pasteurization, the following websites will give you the details

The evidence contained in this site, gives the Canadian Government an obligation to study this bacterium further.Our pasteurization process has to be retested to ensure that Mycobacterium avium paratuberculosis (Map) is eliminated from our milk.

A Canadian Perspective on the Precautionary Approach/Principle Towards the beginning of 2000, the Government began work on a federal initiative to discuss the application of the precautionary approach/principle in science-based regulatory programs. This initiative is in line with the Government's objective of strengthening risk management practices across the federal public service. The precautionary approach / precautionary principle is distinctive within science-based risk management. It recognizes that the absence of full scientific certainty shall not be used as a reason to postpone decisions when faced with the threat of serious or irreversible harm. However, guidance and assurance are required as to the conditions governing the decisions that will be made. Guidance and assurance are particularly needed when a decision must be made regarding a risk of serious or irreversible harm about which there is significant scientific uncertainty. The precautionary approach / precautionary principle primarily affects the development of options and the decision phases, and is ultimately guided by judgement, based on values and priorities. Indeed, Canada has a long-standing history of implementing the precautionary approach in science-based programs of health and safety, environmental protection and natural resources conservation.

In addition, is the Canadian Pasteurization process efficient enough to kill this bacterium, if it is in our milk?  Many renowned doctors and scientists in the field of Crohn's and Johne's (yo-neez) from all over the world say we have cause for concern.
How about our water, is this bacterium in our water?

Once again, the Canadian Government has not tested our Pasteurization Process for milk to assure Canadians that our milk is free from MAP, Mycobacterium Avium Paratuberculosis. WHY?In the United Kingdom researcher's have found the MAP bacterium in a percentage of pasteurized milk at the retail level.

HealingWell.com Forum: Antimycrobacterial Therepy does not prevent crohn's disease relapse

New York: REUTERS Health Information: Antimycobacterial Therapy Does Not Prevent Crohn's Disease Relapse By Will Boggs, MD-------The percentage of antibiotic-treated patients who experienced relapses did not differ significantly from those who received placebo, neither during treatment nor during the ensuing year after trial medications were discontinued, the investigators report. However, a significantly greater percentage of antibiotic-treated patients than placebo-patients had achieved remission at the end of the 16-week induction period.

PLEASE SIGN; U.K Citizens: Please sign this petition for money from the UK Government for funding for the New Dna Crohns Vaccine at St Georges Hospital in London, with Prof John Hermon Taylor. http://petitions.pm.gov.uk/CROHNSVACCINE

IBDanswers: DrugTopics: Crohn's: An Infectious Disease? Australia. Thomas Borody, M.D., director of the Centre for Digestive Diseases, utilizes triple antimycobacterial therapy for his Crohn's patients. Borody said he uses a combination of rifabutin (Mycobutin, Pharmacia), clarithromycin (Biaxin, Abbott), clofazimine (Lamprene, Novartis), and ethambutol for at least three years in his Crohn's disease patients. In his experience, "cures are achieved in 20%-25% of patients and the rest go into total remission." By cure, he means that when his patients are off all medications, they not only have no symptoms, but, endoscopically, they have no inflammation, no histologic evidence of Crohn's disease, and their blood work is negative for markers of inflammation.

Drug Topics: Biologic gets new indication for Crohn's disease-----Adalimumab (Humira, Abbott) is now approved for a second indication for use by patients with moderately to severely active Crohn's disease who are not responding to conventional therapy to reduce signs and symptoms and induce and maintain clinical remission.

Giaconda Ltd.:UPDATE ON PHASE II AND PHASE III TRIALS; Myoconda® – A Combination Antibiotic Therapy for the Treatment of Crohn’s Disease

Biotech Intellegence:----Australian study of anti-MAP treatment in Crohn's Disease published showing highest ever remission rates Giaconda July 18, 2007 Sydney, Australia, Giaconda Ltd (ASX: GIA) announced that the results of the first large-scale, randomized, placebo-controlled clinical study using anti-MAP therapy have been published in the journal Gastroenterology The clinical study, undertaken in 1999, was conducted prior to Giaconda acquiring the intellectual property for the anti-MAP therapy, which has now been further developed and is known as Myoconda®. The publication, titled "Two-Year Combination Antibiotic Therapy with Clarithromycin, Rifabutin and Clofazimine for Crohn's Disease", presents the results of this Phase III trial. These three active ingredients are atypical anti-mycobacterial antibiotics with unique modes of action that work on an intracellular basis and are thus referred to as anti-MAP therapy.

Pub Med: October 1, 2007: Veterinary Microbiology Laboratory, Animal Health Division, Central Institute for Research on Goats, Makhdoom, Farah, Mathura (UP), 281 122 India.

Presence and characterization of Mycobacterium avium subspecies paratuberculosis from clinical and suspected cases of Crohn's disease and in the healthy human population in India

INTERESTING WEBSITE!!! RENSE.COM: The Cause Of Crohn's, IBS And Most Colitis: By Jeff Rense--One of the most crucial missions of rense.com is to stop the beef and dairy poisoning - and deaths - of untold millions of Americans. The massive consumption of these 'products' leads inevitably to the countless numbers of health breakdowns and diseases...everything from cancer to heart disease to Crohn's, IBS and colitis...which are ravaging what's left of this faltering society

January 2006, INFLAMMATORY BOWEL DIS: Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn's disease. BACKGROUND: Mycobacterial avium subspecies paratuberculosis (MAP) infection has been hypothesized as an etiological factor of Crohn's disease (CD). However, the involvement of MAP in the pathophysiology of CD is controversial. The aim of this study is to investigate whether MAP is involved in the pathogenesis of CD with the glutathione S-transferase fusion recombinant protein encoding a portion of insertion element (IS) 900 (IS900-GST), which is specific for MAP.

May 2007, Pub Med: Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion.

ONTARIO, New Directions Research Program, Ministry of Agriculture, Food and Rural Affairs: SR9081 - Mycobacterium Avium Subspecies Paratuberculosis in the Ontario Dairy Industry: Strategies for Detection of the Bacterium in Dairy Products RESEARCHER: Drs. Lucy Mutharia, Dept. of Microbiology and Joseph Odumeru, Laboratory Services Division, UofG

September 20, 2007----FOOD STANDARDS AGENCY: Control of MAP in milk: Mycobacterium avium subsp. paratuberculosis (MAP) is a bacterium that is the cause of a chronic gastrointestinal infection called Johne’s disease in cattle, and other ruminants. There have been claims that it also causes Crohn’s disease, a chronic inflammatory bowel disease of humans that can be severe, prolonged and debilitating. However, experts differ in their opinion on such a link and worldwide there is no consensus. The results of an FSA-commissioned survey which found MAP in approximately 2% of pasteurised milk on retail sale were presented to the Advisory Committee on the Microbiological Safety of Food in September 2000. As a result of the ACMSF's discussions and those of an expert group of stakeholders convened by the Agency, a strategy to control MAP in milk at all stages of the food chain has been produced and can be accessed via the link below.

Mycobacterium avium paratuberculosis in Crohn’s: a study using tissue PCR, in situ PCR and interferon-.. responses Marcel A. Behr, MD Makeda Semret, MD Background • M. avium paratuberculosis (MAP): emerging pathogen, cause of IBD in cattle and other animals • Histopathological similarities between certain types of paratuberculosis (sheep paucibacillary) and Crohn’s disease • Issues in proving link between MAP and Crohn’s: – Technical: accurate diagnostic tests – Conceptual: study design • Case definition/classification of Crohn’s disease • Appropriate controls (PDF)

OttawaStart, April 25, 2007: UCB Pharma Canada Launches National Scholarship Programs for Students Living With Crohn's Disease and Rheumatoid Arthritis Attaining an education is an invaluable asset for most Canadians, but one that is hard enough to obtain without dealing with a chronic illness. With the objective of making education an achievable goal for these students, UCB Pharma Canada announced today the national roll-out of the 2007 UCBeyond Crohn's Disease and Rheumatoid Arthritis Scholarship Programs.

Crohn's Disease in the UK

Scientists have identified a type of bacteria they believe may cause Crohn's disease. The bowel disorder affects 100,000 Britons and can cause a variety of symptoms, ranging from a lack of appetite to chronic diarrhoea and abdominal pain. Its cause is unknown, although one theory is that it can be passed to humans in milk, suggesting that it may be caused by a bacterium.

FDA approves MyocondaR IND for MAP in Crohn's Disease: SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX: GIA) today announced that the US Food and Drug Administration (FDA) has approved the Company's Investigational New Drug application (IND) for the clinical development of MyocondaR to treat patients with Crohn's Disease infected with Mycobacterium avium spp paratuberculosis (MAP

March 19, 2007: Do Frozen Vegetables Pose A Hazard For Your Kids?

Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars T.J. Borody ., S. Bilkey, A.R. Wettstein, S. Leis, G. Pang, S. Tye Centre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock, NSW 2046, Australia Received 13 September 2006; accepted 12 January 2007

Integrating theories of the etiology of Crohn’s Disease: ...........On the etiology of Crohn’s Disease: Questioning the Hypotheses William M. Chamberlin1, Saleh A. Naser2 © Med Sci Monit, 2006; 12(2): RA27-33 PMID: 16449960

Nanomedicine Research Portal: Identifying Mycobacterium avium spp. paratuberculosis (MAP), through magnetic relaxation. .........................C Kaittanis, SA Naser, JM Perez

Peer reviewed journal paper supports use of Giaconda's lead product Myoconda® for Crohn's Disease Giaconda March 22, 2007: Sydney, Australia 22 March 2007. Giaconda Ltd (ASX: GIA) announced that a research paper on the role of Anti-mycobacterial ("Anti-MAP") therapy, in profound healing of ulcerating Crohn's Disease was published in the peer reviewed Digestive and Liver Disease journal. Myoconda®, the company's lead product, is the patented commercial version of the Anti-MAP therapy discussed in the research paper.

Breaking News: February 28, 2007: WELLBEING: RADIO INTERVIEW BETWEEN PROFESSOR TOM BORODY AND IRIS NICHOLS FROM WELLBEING.......Prof. Tom Borody discusses the causes and treatment of Crohn's disease

Researcher's Link Cow's Milk To Crohn's Disease

J Clin Microbiol. 2006 Aug ;44 (8):2942-50 16891515 Evaluation of In Situ Methods Used To Detect Mycobacterium avium subsp. paratuberculosis in Samples from Patients with Crohn's Disease.

Vet Microbiol. 2007 Jan 20; : 17329043 A DNA sequence capture extraction method for detection of Mycobacterium avium subspecies paratuberculosis in feces and tissue samples

J Microbiol Methods. 2007 Jan 9; : 17307264 Improved template DNA preparation procedure for detection of Mycobacterium avium subsp. paratuberculosis in milk by PCR.

Mycobacterium avium ssp. paratuberculosis in foods: current evidence and potential consequences International Journal of Dairy Technology 59 (2), 112–117. doi:10.1111/j.1471-0307.2006.00248.x

Foodborne Pathog Dis. 2006 ;3 (4):457-60 17199528 Modified Culture Protocol for Isolation of Mycobacterium avium subsp. paratuberculosis from Raw Milk.

Am J Gastroenterol. 2006 May ;101 (5):1157-8 16696794 Mycobacterium avium subspecies paratuberculosis: a human pathogen causing most cases of Crohn's disease.

Med Sci Monit. 2006 Mar 28;12 (4):BR130-139 16572045 Inhibition of phagosome maturation and survival of Mycobacterium avium subspecies paratuberculosis in polymorphonuclear leukocytes from Crohn's disease patients. [My paper] John Rumsey , John Valentine , Saleh Naser

J. Dairy Sci. 85:3198-3205 © American Dairy Science Association, 2002........

Effect of Pasteurization on Survival of Mycobacterium paratuberculosis in Milk....... A. Gao*, L. Mutharia, S. Chen*, K. Rahn and J. Odumeru* * Laboratory Services Division, University of Guelph, Guelph, Ontario N1H 8J7, Canada Department of Microbiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada Health Canada, Laboratory for Foodborne Zoonoses, Guelph, Ontario N1G 3W4, Canada

Crohn's & me: UCB Launches $300,000 National Scholarship Program for People Living With Crohn's Disease ATLANTA, March 1 /PRNewswire/ -- UCB, Inc. announced today the national roll out of the 2007 Crohn's Scholarship Program, which will award 30, one-time scholarships of up to $10,000 to people diagnosed with Crohn's disease who demonstrate academic ambition and who are reaching beyond the boundaries of their condition.

The New DNA Crohns Vaccine Summary 2006 , Please send donations to:

Professor John Hermon-Taylor Department of Surgery St George’s, University of London London SW17.0RE, UK. Tel: 020 8767 7631 Fax: 020 8725 5582 Email : jhermon@sgul.ac.uk

February 25, 2006: A vaccine has been developed that could cure more than ,,,,,,,,,,,,,,,,,,150,000 people in the U.K, and millions worldover, who suffer from this crippling digestive illness Crohn's disease, but funding is needed

November 14, 2006: CROHN'S AND COLITIS FOUNDATION: Study Reports Discovery of New Genetic Link to Crohn’s Disease,,,,,,,,,,,,,,,,,,,,A group of North American researchers from leading digestive disease institutes, including the University of Toronto, have released the findings of a large-scale study indicating a new genetic link to Crohn’s disease, which is considered a positive breakthrough in finding a cure for the disease.

The LANCET: EMBARGO: 00:01H (London time) Friday February 24 2006 NEW INSIGHT INTO CAUSE OF CROHN'S DISEASE

BREAKING NEWS: FOR IMMEDIATE RELEASE CONTACT: Kelly Alpert Vest Suffolk Y Jewish Community Center (631)462-9800 Ext 142 (631)462-9462 kvest@syjcc.org www.suffolkyjcc.org Professor Thomas Borody of Australia comes to New York to discuss significant new findings in the fight against Crohn's Disease

HEALTH/SCIENCE: Doctor: Infection is at root of Crohn's disease by Delthia Ricks, Staff Writer, March 16, 2006...................................In the tradition of an Australian Nobel-Prize winner who bucked the establishment, another doctor from down under insists Crohn's disease, an inflammatory bowel disorder, is caused by renegade microbes

Unraveling the mystery of Crohn's disease: .................Could bacteria found in dairy products play a key role in Crohn's disease? By Patrick Perry Published: March/April 2004

Mycobacterium avium paratuberculosis in Crohn’s: a study using tissue PCR, in situ PCR and interferon-.. responses Marcel A. Behr, MD Makeda Semret, MD

Continued next page